Metabolic Dependencies in <i>RAS</i>-Driven Cancers

Abstract excerpt

The ability to inhibit the RAS oncogene has been the holy grail of oncology because of the critical role of this gene in a multitude of tumor types. In addition, RAS-mutant tumors are among the most aggressive and refractory to treatment. Although directly targeting the RAS oncogene has proven challenging, an alternative approach for treating RAS-driven cancers is to inhibit critical downstream events that are...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Autophagy in Disease and Therapy
• Share to Biochemical and Molecular Research
• Share to Cancer, Hypoxia, and Metabolism